Story perspectives

Phase 3 Trial Shows 44% Apnea Reduction, FDA Fast-Tracks Apnimed

6/3/2026

Summary

Story summary

Researchers completed a phase 3 trial of AD109 in the United States and Canada, showing a 44 percent reduction in apnea-hypoxia index.
More than 40 percent of 646 participants moved to a lower severity category, with 18 percent achieving complete control.
The trial reported side effects, with 21 percent of participants stopping treatment because of them.
Apnimed received FDA Fast Track status for the drug and filed a New Drug Application expecting a first-quarter 2027 decision.

1 of 1

Story summary

Researchers completed a phase 3 trial of AD109 in the United States and Canada, showing a 44 percent reduction in apnea-hypoxia index.
More than 40 percent of 646 participants moved to a lower severity category, with 18 percent achieving complete control.
The trial reported side effects, with 21 percent of participants stopping treatment because of them.
Apnimed received FDA Fast Track status for the drug and filed a New Drug Application expecting a first-quarter 2027 decision.